Bulk Manufacturer of Controlled Substances Application: Noramco Inc., 60898 [2018-25874]
Download as PDF
<![CDATA[
60898
Federal Register / Vol. 83, No. 228 / Tuesday, November 27, 2018 / Notices
The company plans to import the listed
controlled substances for analytical
research, testing and clinical trials.
Dated: November 16, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018–25869 Filed 11–26–18; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
SUPPLEMENTARY INFORMATION:
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Application: Noramco Inc.
ACTION:
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before January 28, 2019.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
DATES:
Notice of application.
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.33(a), this is notice that on July 4,
2018, Noramco Inc., 1550 Olympic Dr.
Athens, Georgia 30601 applied to be
registered as a bulk manufacturer for the
basic classes of controlled substances:
Controlled substance
Drug code
amozie on DSK3GDR082PROD with NOTICES1
Cathinone ................................................................................................................................................................
Gamma Hydroxybutyric Acid ...................................................................................................................................
Marihuana ................................................................................................................................................................
Tetrahydrocannabinols ............................................................................................................................................
Codeine-N-oxide ......................................................................................................................................................
Dihydromorphine .....................................................................................................................................................
Hydromorphinol .......................................................................................................................................................
Morphine-N-oxide ....................................................................................................................................................
Amphetamine ..........................................................................................................................................................
Lisdexamfetamine ...................................................................................................................................................
Methylphenidate ......................................................................................................................................................
Nabilone ..................................................................................................................................................................
Codeine ...................................................................................................................................................................
Dihydrocodeine ........................................................................................................................................................
Oxycodone ..............................................................................................................................................................
Hydromorphone .......................................................................................................................................................
Hydrocodone ...........................................................................................................................................................
Morphine ..................................................................................................................................................................
Oripavine .................................................................................................................................................................
Thebaine ..................................................................................................................................................................
Opium tincture .........................................................................................................................................................
Oxymorphone ..........................................................................................................................................................
Noroxymorphone .....................................................................................................................................................
Alfentanil ..................................................................................................................................................................
Sufentanil .................................................................................................................................................................
Carfentanil ...............................................................................................................................................................
Tapentadol ...............................................................................................................................................................
Fentanyl ...................................................................................................................................................................
The company plans to manufacture
bulk active pharmaceutical ingredients
(APIs) and reference standards for
distribution to their customers.
In reference to drug codes 7360
(marihuana) and 7370
(tetrahydrocannabinols), the company
plans to bulk manufacture these drugs
as synthetic. No other activities for these
drug codes are authorized for this
registration.
Dated: November 16, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018–25874 Filed 11–26–18; 8:45 am]
BILLING CODE 4410–09–P
Jkt 247001
The registrant listed below
has applied for and has been granted
registration by the Drug Enforcement
Administration (DEA) as an importer of
schedule I or II controlled substances.
The
company listed below applied to be
registered as an importer of various
basic classes of controlled substances.
Information on the previously published
notice is listed in the table below. No
comments or objections were submitted
and no requests for a hearing were
submitted for this notice.
SUPPLEMENTARY INFORMATION:
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
ACTION:
17:45 Nov 26, 2018
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
SUMMARY:
Importer of Controlled Substances
Registration
VerDate Sep<11>2014
1235
2010
7360
7370
9053
9145
9301
9307
1100
1205
1724
7379
9050
9120
9143
9150
9193
9300
9330
9333
9630
9652
9668
9737
9740
9743
9780
9801
Schedule
PO 00000
Notice of registration.
Frm 00078
Fmt 4703
Sfmt 4703
E:\FR\FM\27NON1.SGM
27NON1
]]>Agencies
[Federal Register Volume 83, Number 228 (Tuesday, November 27, 2018)]
[Notices]
[Page 60898]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-25874]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Bulk Manufacturer of Controlled Substances Application: Noramco
Inc.
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration on or before January 28, 2019.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers, importers, and exporters of
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been redelegated
to the Assistant Administrator of the DEA Diversion Control Division
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0,
appendix to subpart R.
In accordance with 21 CFR 1301.33(a), this is notice that on July
4, 2018, Noramco Inc., 1550 Olympic Dr. Athens, Georgia 30601 applied
to be registered as a bulk manufacturer for the basic classes of
controlled substances:
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Cathinone....................... 1235 I
Gamma Hydroxybutyric Acid....... 2010 I
Marihuana....................... 7360 I
Tetrahydrocannabinols........... 7370 I
Codeine-N-oxide................. 9053 I
Dihydromorphine................. 9145 I
Hydromorphinol.................. 9301 I
Morphine-N-oxide................ 9307 I
Amphetamine..................... 1100 II
Lisdexamfetamine................ 1205 II
Methylphenidate................. 1724 II
Nabilone........................ 7379 II
Codeine......................... 9050 II
Dihydrocodeine.................. 9120 II
Oxycodone....................... 9143 II
Hydromorphone................... 9150 II
Hydrocodone..................... 9193 II
Morphine........................ 9300 II
Oripavine....................... 9330 II
Thebaine........................ 9333 II
Opium tincture.................. 9630 II
Oxymorphone..................... 9652 II
Noroxymorphone.................. 9668 II
Alfentanil...................... 9737 II
Sufentanil...................... 9740 II
Carfentanil..................... 9743 II
Tapentadol...................... 9780 II
Fentanyl........................ 9801 II
------------------------------------------------------------------------
The company plans to manufacture bulk active pharmaceutical
ingredients (APIs) and reference standards for distribution to their
customers.
In reference to drug codes 7360 (marihuana) and 7370
(tetrahydrocannabinols), the company plans to bulk manufacture these
drugs as synthetic. No other activities for these drug codes are
authorized for this registration.
Dated: November 16, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018-25874 Filed 11-26-18; 8:45 am]
BILLING CODE 4410-09-P
